Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients

Alaa Hassan ElBaz80 enrolled

Overview

The investigator study evaluate the effect of different lipid lowering agents on the progression of diabetic retinopathy and other reduction of cardiovascular risk of diabetic patients

The investigator study compare the effect of lipid lowering agent on the enhancement of visual acuity and on reduction of macular edema in patients with diabetic retinopathy and also compare their effect on reduction of cardiovascular risk on diabetic patients via assessment of ASCVD risk score

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Retinopathy

Interventions

Simvastatin 40mgDRUG

Drugs that lower lipid level

Fenofibrate 200mgDRUG

Drugs that lower lipid levels

Omega 3 fatty acidDRUG

Drugs that lower lipid levels

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * type 2diabetes * Non proliferative diabetic retinopathy Exclusion Criteria: * Uncontrolled glycemic level * proliferative diabetic retinopathy

Outcomes

Primary Outcomes

The 80 participants will be evaluated through reduction of macular edema

assessed by ocular coherence tomography

Time frame: 18 weeks

Secondary Outcomes

The 80 participants will be evaluated through reduction of cardiovascular risk

assessed by ASCVD risk score

Time frame: 18 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.